Innovative WEF-style forums will gather experts from the corporate, neuroscience, and clinical fields to discuss breakthroughs in neurodegeneration research. These sessions aim to advance our understanding and treatment of Alzheimer’s and Parkinson’s diseases by exchanging new insights and addressing current challenges. Each forum features brief introductions by participants, followed by an audience Q&A, with media coverage to share progress in the field.

Forum Date & Title

Co-Moderators

Discussants

Wednesday, April 2, 2025

INTEGRATING BLOOD-BASED, CSF AND IMAGING BIOMARKERS WITH DIGITAL TOOLS AND AI IN MCI & AD: HOW CLOSE ARE WE TO VALIDATION IN STANDARD OR PRECISION MEDICINE?

• Melissa Murray
  (USA)
• Oskar Hansson
  (Sweden) 

IMPROVING THE THERAPEUTIC POTENTIAL OF IMMUNOTHERAPIES IN AD – CAN NOVEL STRATEGIES OR NEXT GENERATION DRUGS HALT OR FURTHER DELAY DISEASE PROGRESSION?

• Suzanne Hendrix
  (USA)
• Rudy Tanzi
  (USA)

Thursday, April 3, 2025

TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION – WHAT COULD BE PROMISING STRATEGIES? SMALL MOLECULES FOR SYMPTOMATIC & DISEASE MODIFICATION?

• Jeffrey Cummings
  (USA)
• Howard Fillit
  (USA)

Friday, April 4, 2025

NOVEL APPROACHES TO ACCELERATE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES LINKED TO PD, LBD AND MSA

• Jamie Eberling
  (USA)
• Walter Koroshetz
  (USA)

CHALLENGES AND OPPORTUNITIES FOR ANTI-TAU THERAPIES IN CLINICAL TRIALS – HOW CAN WE MAKE HOPES COME TRUE?

• Manfred Windisch
  (Austria)
• Luc Buee
  (France)

Saturday, April 5, 2025

THERAPY FOR AD, PD & LBD: NOVEL TRANSLATIONAL MODELS, NEW RECEPTOR- AND NEUROINFLAMMATION-BASED TARGETS – HOW CLOSE ARE WE TO SUCCESS?

• Cynthia Lemere
  (USA)
• Meg Smith
  (USA)

DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TO APPROVAL – HOW TO DEFINE SUCCESS?S?

• Angela Genge
  (Canada)Laura
• Ranum
  (USA)